-
Something wrong with this record ?
Ghrelin/GHS-R1A antagonism in memory test and its effects on central molecular signaling involved in addiction in rats
M. Lapka, C. Charalambous, A. Khryakova, A. Certilina, J. Novotny, L. Hejnova, M. Sustkova-Fiserova
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Actins MeSH
- Ghrelin pharmacology MeSH
- Rats MeSH
- Methamphetamine * pharmacology MeSH
- Calcium-Calmodulin-Dependent Protein Kinase Type 2 MeSH
- Receptors, Ghrelin * MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Central ghrelin signaling seems to play important role in addiction as well as memory processing. Antagonism of the growth hormone secretagogue receptor (GHS-R1A) has been recently proposed as a promising tool for the unsatisfactory drug addiction therapy. However, molecular aspects of GHS-R1A involvement in specific brain regions remain unclear. The present study demonstrated for the first time that acute as well as subchronic (4 days) administration of the experimental GHS-R1A antagonist JMV2959 in usual intraperitoneal doses including 3 mg/kg, had no influence on memory functions tested in the Morris Water Maze in rats as well as no significant effects on the molecular markers linked with memory processing in selected brain areas in rats, specifically on the β-actin, c-Fos, two forms of the calcium/calmodulin-dependent protein kinase II (CaMKII, p-CaMKII) and the cAMP-response element binding protein (CREB, p-CREB), within the medial prefrontal cortex (mPFC), nucleus accumbens (NAc), dorsal striatum, and hippocampus (HIPP). Furthermore, following the methamphetamine intravenous self-administration in rats, the 3 mg/kg JMV2959 pretreatment significantly reduced or prevented the methamphetamine-induced significant decrease of hippocampal β-actin and c-Fos as well as it prevented the significant decrease of CREB in the NAC and mPFC. These results imply, that the GHS-R1A antagonist/JMV2959 might reduce/prevent some of the memory-linked molecular changes elicited by methamphetamine addiction within brain structures associated with memory (HIPP), reward (NAc), and motivation (mPFC), which may contribute to the previously observed significant JMV2959-induced reduction of the methamphetamine self-administration and drug-seeking behavior in the same animals. Further research is necessary to corroborate these results.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010666
- 003
- CZ-PrNML
- 005
- 20230801132555.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pbb.2023.173528 $2 doi
- 035 __
- $a (PubMed)36870422
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Lapka, Marek $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10 10000, Czech Republic. Electronic address: marek.lapka@lf3.cuni.cz
- 245 10
- $a Ghrelin/GHS-R1A antagonism in memory test and its effects on central molecular signaling involved in addiction in rats / $c M. Lapka, C. Charalambous, A. Khryakova, A. Certilina, J. Novotny, L. Hejnova, M. Sustkova-Fiserova
- 520 9_
- $a Central ghrelin signaling seems to play important role in addiction as well as memory processing. Antagonism of the growth hormone secretagogue receptor (GHS-R1A) has been recently proposed as a promising tool for the unsatisfactory drug addiction therapy. However, molecular aspects of GHS-R1A involvement in specific brain regions remain unclear. The present study demonstrated for the first time that acute as well as subchronic (4 days) administration of the experimental GHS-R1A antagonist JMV2959 in usual intraperitoneal doses including 3 mg/kg, had no influence on memory functions tested in the Morris Water Maze in rats as well as no significant effects on the molecular markers linked with memory processing in selected brain areas in rats, specifically on the β-actin, c-Fos, two forms of the calcium/calmodulin-dependent protein kinase II (CaMKII, p-CaMKII) and the cAMP-response element binding protein (CREB, p-CREB), within the medial prefrontal cortex (mPFC), nucleus accumbens (NAc), dorsal striatum, and hippocampus (HIPP). Furthermore, following the methamphetamine intravenous self-administration in rats, the 3 mg/kg JMV2959 pretreatment significantly reduced or prevented the methamphetamine-induced significant decrease of hippocampal β-actin and c-Fos as well as it prevented the significant decrease of CREB in the NAC and mPFC. These results imply, that the GHS-R1A antagonist/JMV2959 might reduce/prevent some of the memory-linked molecular changes elicited by methamphetamine addiction within brain structures associated with memory (HIPP), reward (NAc), and motivation (mPFC), which may contribute to the previously observed significant JMV2959-induced reduction of the methamphetamine self-administration and drug-seeking behavior in the same animals. Further research is necessary to corroborate these results.
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a receptory ghrelinu $7 D054440
- 650 _2
- $a ghrelin $x farmakologie $7 D054439
- 650 _2
- $a aktiny $7 D000199
- 650 _2
- $a proteinkinasa závislá na vápníku a kalmodulinu typ 2 $7 D054732
- 650 12
- $a methamfetamin $x farmakologie $7 D008694
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Charalambous, Chrysostomos $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10 10000, Czech Republic. Electronic address: chrysostomos.charalambous@lf3.cuni.cz
- 700 1_
- $a Khryakova, Anna $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10 10000, Czech Republic
- 700 1_
- $a Certilina, Alina $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10 10000, Czech Republic
- 700 1_
- $a Novotny, Jiri $u Department of Physiology, Faculty of Science, Charles University, Vinicna 7, Prague 2 128 00, Czech Republic. Electronic address: jiri.novotny@natur.cuni.cz
- 700 1_
- $a Hejnova, Lucie $u Department of Physiology, Faculty of Science, Charles University, Vinicna 7, Prague 2 128 00, Czech Republic. Electronic address: lucie.hejnova@natur.cuni.cz
- 700 1_
- $a Sustkova-Fiserova, Magdalena $u Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruska 87, Prague 10 10000, Czech Republic. Electronic address: magdalena.sustkova@lf3.cuni.cz
- 773 0_
- $w MED00003794 $t Pharmacology, biochemistry, and behavior $x 1873-5177 $g Roč. 224, č. - (2023), s. 173528
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36870422 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132552 $b ABA008
- 999 __
- $a ok $b bmc $g 1963238 $s 1196931
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 224 $c - $d 173528 $e 20230303 $i 1873-5177 $m Pharmacology, biochemistry and behavior $n Pharmacol Biochem Behav $x MED00003794
- LZP __
- $a Pubmed-20230718
